AstraZeneca Covid-19 Vaccine Trials Resume in the U.K.
September 12 2020 - 11:33AM
Dow Jones News
By Peter Loftus
AstraZeneca PLC said Saturday clinical trials for its
experimental coronavirus vaccine have resumed in the U.K. after
regulators concluded it was safe to do so, following a pause in
studies globally after a person who received the vaccine had an
unexplained illness.
Trials in other countries, including the U.S., remain paused
while AstraZeneca works with national health authorities, the
company said.
AstraZeneca said Tuesday it paused trials globally of a vaccine
it licensed from the University of Oxford after a vaccinated woman
in the U.K. experienced the unexplained illness, which a U.S.
official described as a spinal cord problem.
The pause gave independent committees and country regulators
time to evaluate the case and determine whether it would be safe
for testing to begin again.
A U.K. committee has concluded its investigation and recommended
to the U.K. Medicines & Healthcare products Regulatory Agency
it would be safe to resume the trials. The regulatory agency
confirmed that it was safe to resume, the company said.
The MHRA couldn't immediately be reached for comment.
AstraZeneca said it couldn't disclose further medical
information.
Write to Peter Loftus at peter.loftus@wsj.com
(END) Dow Jones Newswires
September 12, 2020 11:18 ET (15:18 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
